PortalPublikationenImmuno-oncology in GI tumours

Immuno-oncology in GI tumours

Standard

Immuno-oncology in GI tumours : Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. / Stein, Alexander; Markus, Moehler; Jörg, Trojan; Eray, Goekkurt; Vogel, Arndt.

in: CRIT REV ONCOL HEMAT, Jahrgang 130, 10.2018, S. 13-26.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Transfer

Harvard

Stein, A, Markus, M, Jörg, T, Eray, G & Vogel, A 2018, 'Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists', CRIT REV ONCOL HEMAT, Jg. 130, S. 13-26. https://doi.org/10.1016/j.critrevonc.2018.07.001

APA

Stein, A., Markus, M., Jörg, T., Eray, G., & Vogel, A. (2018). Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. CRIT REV ONCOL HEMAT, 130, 13-26. https://doi.org/10.1016/j.critrevonc.2018.07.001

Vancouver

Stein A, Markus M, Jörg T, Eray G, Vogel A. Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. CRIT REV ONCOL HEMAT. 2018 Okt;130:13-26. https://doi.org/10.1016/j.critrevonc.2018.07.001

Bibtex

@article{6323381699614cc6933c4f4735d543f9,
title = "Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists",
abstract = "The use of immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers. Since 2014, these antagonists of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors. Phase II trials and phase I expansion cohorts demonstrate clinical activity in patients with oesophageal, gastric, colorectal, anal and hepatic cancer. Signals of outstanding efficacy are particularly observed in biomarker selected populations and for certain combination regimen. Comprehensive phase III development programs have been initiated in oesophageal and gastric cancer, with randomized trials ongoing in hepatocellular and colorectal cancer as well.",
keywords = "Journal Article, Review",
author = "Alexander Stein and Moehler Markus and Trojan J{\"o}rg and Goekkurt Eray and Arndt Vogel",
note = "Copyright {\textcopyright} 2018 Elsevier B.V. All rights reserved.",
year = "2018",
month = oct,
doi = "10.1016/j.critrevonc.2018.07.001",
language = "English",
volume = "130",
pages = "13--26",
journal = "CRIT REV ONCOL HEMAT",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Immuno-oncology in GI tumours

T2 - Clinical evidence and emerging trials of PD-1/PD-L1 antagonists

AU - Stein, Alexander

AU - Markus, Moehler

AU - Jörg, Trojan

AU - Eray, Goekkurt

AU - Vogel, Arndt

N1 - Copyright © 2018 Elsevier B.V. All rights reserved.

PY - 2018/10

Y1 - 2018/10

N2 - The use of immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers. Since 2014, these antagonists of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors. Phase II trials and phase I expansion cohorts demonstrate clinical activity in patients with oesophageal, gastric, colorectal, anal and hepatic cancer. Signals of outstanding efficacy are particularly observed in biomarker selected populations and for certain combination regimen. Comprehensive phase III development programs have been initiated in oesophageal and gastric cancer, with randomized trials ongoing in hepatocellular and colorectal cancer as well.

AB - The use of immune checkpoint inhibitors constitutes an emerging therapeutic field for the therapy of gastrointestinal (GI) malignancies following the recent FDA approvals of PD-1 inhibitors for esophago-gastric adenocarcinoma, hepatocellular carcinoma and for microsatellite-instable tumors, which are mainly colorectal cancers. This paper reviews the clinical evidence end of 2017 and discusses the clinical development programs of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in GI-tract cancers. Since 2014, these antagonists of the PD-1/PD-L1 axis have gained approval for use in numerous other tumors. Phase II trials and phase I expansion cohorts demonstrate clinical activity in patients with oesophageal, gastric, colorectal, anal and hepatic cancer. Signals of outstanding efficacy are particularly observed in biomarker selected populations and for certain combination regimen. Comprehensive phase III development programs have been initiated in oesophageal and gastric cancer, with randomized trials ongoing in hepatocellular and colorectal cancer as well.

KW - Journal Article

KW - Review

U2 - 10.1016/j.critrevonc.2018.07.001

DO - 10.1016/j.critrevonc.2018.07.001

M3 - SCORING: Review article

C2 - 30196908

VL - 130

SP - 13

EP - 26

JO - CRIT REV ONCOL HEMAT

JF - CRIT REV ONCOL HEMAT

SN - 1040-8428

ER -